Literature DB >> 9160467

Transfer of genes to chondrocytic cells of the lumbar spine. Proposal for a treatment strategy of spinal disorders by local gene therapy.

P Wehling1, K P Schulitz, P D Robbins, C H Evans, J A Reinecke.   

Abstract

STUDY
DESIGN: In the current study, chondrocytic cells from bovine intervertebral end plates were cultivated in vitro and modified genetically.
OBJECTIVE: The authors intended to perform isolation and cultivation of cells from bovine end plates of the spine. They also intended to show, in principle, the feasibility of introducing exogenous genes into chondrocytic cells from bovine intervertebral end plates by way of retroviral vectors. SUMMARY OF BACKGROUND DATA: The involvement of cytokines in the destruction of articular cartilage is established. It appears possible that similar mechanisms may play a role in intervertebral disc degeneration and other spinal disorders. Conventional medication and surgery of intervertebral disc degeneration addresses neither the pathophysiology nor the chronicity of the disease. Therapeutic proteins carry great potential as locally produced drugs after transfer of their cognate genes to the sites of interest.
METHODS: Vertebral end plate tissue was obtained from bovine os coccygis. Chondrocytic cells were isolated and cultured in vitro. The bacterial beta-galactosidase (LacZ) gene and, alternatively, the complementary DNA (DNA copy of the mRNA) of the human interleukin-1 receptor antagonist were introduced into the isolated cells by retrovirus mediated gene transfer. beta-galactosidase activity was determined by staining, and interleukin-1 receptor antagonist protein was quantitated by enzyme-linked immunosorbent assay.
RESULTS: Isolation and cultivation of chondrocytic end plate cells is possible. Native cells continue to grow in culture for more than 2 months. Transfer of the beta-galactosidase gene to cultured cells resulted in approximately 1% beta-galactosidase positive cells. Transfer of the interleukin-1 receptor antagonist complementary DNA resulted in the production of 24 ng/ml/10(6) cells interleukin-1 receptor antagonist protein in 48 hours.
CONCLUSIONS: The introduction of exogenous therapeutic genes into cells from the intervertebral end plate opens the possibility for a local gene-based treatment of intervertebral disc degeneration. This approach avoids some of the shortcomings of conventional drug- and surgery-based treatments and has the potential to be specific, effective, and appropriate to the chronicity of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160467     DOI: 10.1097/00007632-199705150-00008

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  14 in total

1.  A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration.

Authors:  Christine L Le Maitre; Anthony J Freemont; Judith A Hoyland
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

Review 2.  Biological treatment strategies for disc degeneration: potentials and shortcomings.

Authors:  Günther Paesold; Andreas G Nerlich; Norbert Boos
Journal:  Eur Spine J       Date:  2006-09-16       Impact factor: 3.134

Review 3.  Prevention of disc degeneration with growth factors.

Authors:  Koichi Masuda; Howard S An
Journal:  Eur Spine J       Date:  2006-07-25       Impact factor: 3.134

Review 4.  Inflammation in intervertebral disc degeneration and regeneration.

Authors:  Maria Molinos; Catarina R Almeida; Joana Caldeira; Carla Cunha; Raquel M Gonçalves; Mário A Barbosa
Journal:  J R Soc Interface       Date:  2015-03-06       Impact factor: 4.118

Review 5.  Gene therapy approach for disc degeneration and associated spinal disorders.

Authors:  Kotaro Nishida; Teppei Suzuki; Kenichiro Kakutani; Takashi Yurube; Koichiro Maeno; Masahiro Kurosaka; Minoru Doita
Journal:  Eur Spine J       Date:  2008-11-13       Impact factor: 3.134

6.  Molecular and genetic advances in the regeneration of the intervertebral disc.

Authors:  Tristan Maerz; Harry Herkowitz; Kevin Baker
Journal:  Surg Neurol Int       Date:  2013-03-22

7.  Lumbar degenerative disc disease: current and future concepts of diagnosis and management.

Authors:  Fadi Taher; David Essig; Darren R Lebl; Alexander P Hughes; Andrew A Sama; Frank P Cammisa; Federico P Girardi
Journal:  Adv Orthop       Date:  2012-04-02

Review 8.  Growth factors and anticatabolic substances for prevention and management of intervertebral disc degeneration.

Authors:  Umile Giuseppe Longo; Stefano Petrillo; Edoardo Franceschetti; Nicola Maffulli; Vincenzo Denaro
Journal:  Stem Cells Int       Date:  2011-11-03       Impact factor: 5.443

9.  Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study.

Authors:  Christine L Le Maitre; Judith A Hoyland; Anthony J Freemont
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 10.  Molecular therapy for disk degeneration and pain.

Authors:  Fackson Mwale
Journal:  Global Spine J       Date:  2013-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.